BSE: 542650 | NSE: METROPOLIS | Hospital & Healthcare Services | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Metropolis Healthcare Ltd is a good quality company.
The key valuation ratios of Metropolis Healthcare Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Metropolis Healthcare Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 27.5% | 40.1% | 54.3% | 45.2% | 44.8% | 37.8% | 41.6% | 34.4% | 19.8% | 18.7% | - |
| Value Creation Index ⓘ | 1.0 | 2.0 | 3.0 | 2.4 | 2.2 | 1.8 | 2.1 | 1.6 | 0.5 | 0.4 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 455 | 524 | 545 | 647 | 761 | 856 | 998 | 1,228 | 1,148 | 1,208 | 1,285 |
| Sales YoY Gr. | - | 15.2% | 4% | 18.8% | 17.6% | 12.5% | 16.5% | 23.1% | -6.5% | 5.2% | - |
| Adj EPS ⓘ | 11.9 | 16 | 19.6 | 20.9 | 24.1 | 25.2 | 36.2 | 39.8 | 27.9 | 25.8 | 28.9 |
| YoY Gr. | - | 34.9% | 22.5% | 6.4% | 15.6% | 4.3% | 43.8% | 9.9% | -29.8% | -7.7% | - |
| BVPS (₹) ⓘ | 70.4 | 53.4 | 65.1 | 83.2 | 82.9 | 103 | 136.6 | 170.9 | 191.5 | 212.5 | 230.9 |
| Adj Net Profit ⓘ | 60.9 | 79.5 | 97.4 | 104 | 121 | 127 | 185 | 203 | 143 | 132 | 148 |
| Cash Flow from Ops. ⓘ | 69.7 | 88.2 | 102 | 104 | 90.2 | 215 | 249 | 253 | 247 | 264 | - |
| Debt/CF from Ops. ⓘ | 0.2 | 0.1 | 0 | 0 | 0.2 | 0 | 0 | 1 | 0.3 | 0 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 11.5% | 9.7% | 6.6% | 5.2% | ||||
| Adj EPS ⓘ | 9% | 1.3% | -10.7% | -7.7% | ||||
| BVPSⓘ | 13.1% | 20.7% | 15.9% | 10.9% | ||||
| Share Price | - | 7.7% | -12.1% | 24.3% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 16.9 | 25.4 | 33.1 | 28.1 | 29.1 | 27 | 30.1 | 25.6 | 15.3 | 12.7 | 13 |
| Op. Profit Mgn % ⓘ | 25.9 | 26.2 | 28.4 | 28 | 27 | 27.8 | 29.3 | 28.3 | 25.7 | 24.4 | 24.4 |
| Net Profit Mgn % ⓘ | 14.9 | 16.8 | 18.9 | 17.2 | 16.4 | 14.9 | 18.6 | 16.6 | 12.5 | 11 | 11.5 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.3 | 0.1 | 0 | 0 |
| Working Cap Days ⓘ | 0 | 82 | 82 | 160 | 218 | 187 | 127 | 116 | 153 | 137 | 47 |
| Cash Conv. Cycle ⓘ | 0 | 22 | 18 | 23 | 33 | 18 | -8 | -9 | 0 | -2 | 15 |
Sales growth is good in last 4 quarters at 11.40%
Return on Equity has declined versus last 3 years average to 13.00%
Sales growth has been subdued in last 3 years 6.56%
Net Profit has been subdued in last 3 years -10.69%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 25.8 | 28.9 |
| TTM Sales (₹ Cr.) | 1,169 | 1,285 |
| BVPS (₹.) ⓘ | 215.7 | 230.9 |
| Reserves (₹ Cr.) ⓘ | 1,096 | 1,174 |
| P/BV ⓘ | 9.56 | 8.93 |
| PE ⓘ | 80.08 | 71.42 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 1450.05 / 2306.85 |
| All Time Low / High (₹) | 904.85 / 3579.00 |
| Market Cap (₹ Cr.) | 10,572 |
| Equity (₹ Cr.) | 10.3 |
| Face Value (₹) | 2 |
| Industry PE ⓘ | 41.2 |
| Pledged * | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 455 | 524 | 545 | 647 | 761 | 856 | 998 | 1,228 | 1,148 | 1,208 |
| Operating Expenses ⓘ | 337 | 388 | 391 | 469 | 557 | 619 | 708 | 883 | 857 | 920 |
| Manufacturing Costs | 21 | 18 | 20 | 29 | 30 | 35 | 46 | 63 | 46 | 62 |
| Material Costs | 129 | 143 | 135 | 146 | 174 | 204 | 252 | 276 | 253 | 243 |
| Employee Cost | 95 | 116 | 128 | 147 | 176 | 190 | 199 | 233 | 253 | 276 |
| Other Costs ⓘ | 92 | 111 | 108 | 147 | 177 | 190 | 211 | 310 | 305 | 339 |
| Operating Profit ⓘ | 118 | 136 | 153 | 178 | 204 | 237 | 290 | 346 | 291 | 288 |
| Operating Profit Margin (%) | 25.8% | 26.0% | 28.2% | 27.6% | 26.8% | 27.7% | 29.0% | 28.1% | 25.4% | 23.8% |
| Other Income ⓘ | 6 | 22 | 26 | 8 | 8 | 9 | 12 | 20 | 17 | 9 |
| Interest ⓘ | 2 | 2 | 2 | 4 | 4 | 13 | 12 | 25 | 32 | 28 |
| Depreciation ⓘ | 21 | 21 | 17 | 19 | 20 | 39 | 46 | 63 | 89 | 94 |
| Exceptional Items ⓘ | 0 | -8 | 0 | 0 | 0 | -25 | 0 | 16 | 0 | 0 |
| Profit Before Tax ⓘ | 101 | 128 | 160 | 164 | 187 | 169 | 244 | 293 | 188 | 175 |
| Tax ⓘ | 33 | 46 | 53 | 52 | 63 | 41 | 61 | 79 | 44 | 46 |
| Profit After Tax | 68 | 82 | 107 | 112 | 124 | 128 | 183 | 215 | 143 | 128 |
| PAT Margin (%) | 14.9% | 15.6% | 19.7% | 17.3% | 16.2% | 14.9% | 18.4% | 17.5% | 12.5% | 10.6% |
| Adjusted EPS (₹) | 11.9 | 14.8 | 20.5 | 21.0 | 23.9 | 25.2 | 35.8 | 41.9 | 27.9 | 25.0 |
| Dividend Payout Ratio (%) | 0% | 104% | 49% | 0% | 55% | 32% | 22% | 19% | 29% | 16% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 361 | 265 | 323 | 413 | 416 | 521 | 698 | 874 | 981 | 1,088 |
| Share Capital ⓘ | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves ⓘ | 351 | 255 | 314 | 404 | 406 | 511 | 688 | 864 | 971 | 1,078 |
| Minority Interest | 23 | 20 | 21 | 14 | 1 | 2 | 1 | 2 | 2 | 3 |
| Debt | 7 | 3 | 1 | 1 | 18 | 0 | 0 | 259 | 79 | 0 |
| Long Term Debt | 7 | 3 | 0 | 0 | 0 | 0 | 0 | 159 | 29 | 0 |
| Short Term Debt | 0 | 0 | 0 | 0 | 18 | 0 | 0 | 100 | 50 | 0 |
| Trade Payables | 34 | 38 | 36 | 35 | 43 | 85 | 111 | 103 | 94 | 99 |
| Others Liabilities ⓘ | 43 | 65 | 131 | 346 | 325 | 322 | 249 | 507 | 554 | 557 |
| Total Liabilities ⓘ | 468 | 391 | 512 | 810 | 803 | 930 | 1,059 | 1,745 | 1,710 | 1,748 |
Fixed Assets | ||||||||||
| Gross Block | 260 | 273 | 220 | 246 | 271 | 366 | 438 | 1,223 | 1,344 | 1,493 |
| Accumulated Depreciation | 107 | 125 | 17 | 39 | 58 | 70 | 95 | 165 | 224 | 316 |
| Net Fixed Assetsⓘ | 153 | 148 | 202 | 207 | 213 | 296 | 343 | 1,059 | 1,121 | 1,177 |
| CWIP ⓘ | 0 | 1 | 1 | 0 | 6 | 3 | 0 | 6 | 20 | 0 |
| Investmentsⓘ | 170 | 80 | 142 | 102 | 33 | 14 | 10 | 16 | 15 | 55 |
| Inventories | 18 | 18 | 14 | 21 | 26 | 24 | 41 | 51 | 45 | 39 |
| Trade Receivables | 76 | 77 | 80 | 101 | 137 | 128 | 123 | 135 | 122 | 126 |
| Cash Equivalents | 29 | 43 | 41 | 60 | 80 | 210 | 420 | 167 | 93 | 71 |
| Others Assetsⓘ | 22 | 25 | 32 | 318 | 308 | 253 | 123 | 311 | 296 | 280 |
| Total Assets ⓘ | 468 | 391 | 512 | 810 | 803 | 930 | 1,059 | 1,745 | 1,710 | 1,748 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 70 | 88 | 102 | 104 | 90 | 215 | 249 | 253 | 247 | 264 |
| PBT ⓘ | 101 | 128 | 160 | 164 | 187 | 169 | 244 | 293 | 188 | 175 |
| Adjustment ⓘ | 16 | 9 | -3 | 21 | 22 | 83 | 77 | 59 | 104 | 121 |
| Changes in Working Capital ⓘ | -17 | -3 | -4 | -23 | -51 | 28 | -15 | -16 | 7 | 5 |
| Tax Paid ⓘ | -32 | -47 | -51 | -58 | -67 | -64 | -57 | -83 | -52 | -37 |
| Cash Flow From Investing Activity ⓘ | -56 | 91 | -86 | 2 | 35 | -105 | 62 | -738 | 47 | -89 |
| Capex | -24 | -13 | -16 | -18 | -23 | -36 | -28 | -31 | -52 | -64 |
| Net Investments | -35 | 104 | -37 | 17 | 56 | -73 | 85 | -80 | 93 | -27 |
| Others ⓘ | 3 | -1 | -33 | 3 | 3 | 4 | 5 | -627 | 6 | 2 |
| Cash Flow From Financing Activityⓘ | -10 | -166 | -17 | -87 | -118 | -55 | -33 | 163 | -292 | -181 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | -3 | 32 | 34 | 2 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | -6 | 0 | -4 | 0 | 0 | -18 | 0 | 159 | 0 | 0 |
| Interest Paid ⓘ | -2 | -1 | 0 | 0 | 0 | -41 | -7 | -18 | -27 | -22 |
| Dividend Paid ⓘ | -1 | -84 | 0 | -53 | -67 | -8 | -41 | -41 | -41 | -20 |
| Others ⓘ | 0 | -81 | -13 | -34 | -48 | -21 | -19 | 61 | -224 | -138 |
| Net Cash Flow ⓘ | 4 | 13 | -1 | 19 | 7 | 55 | 278 | -322 | 2 | -7 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 18.77 | 26.16 | 36.47 | 30.38 | 29.82 | 27.21 | 30.07 | 27.31 | 15.46 | 12.42 |
| ROCE (%) | 27.47 | 40.06 | 54.28 | 45.22 | 44.77 | 37.79 | 41.6 | 34.39 | 19.83 | 18.73 |
| Asset Turnover Ratio | 0.97 | 1.22 | 1.21 | 0.98 | 0.94 | 0.99 | 1 | 0.88 | 0.66 | 0.7 |
| PAT to CFO Conversion(x) | 1.03 | 1.07 | 0.95 | 0.93 | 0.73 | 1.68 | 1.36 | 1.18 | 1.73 | 2.06 | Working Capital Days |
| Receivable Days | 61 | 53 | 53 | 51 | 57 | 56 | 46 | 38 | 41 | 38 |
| Inventory Days | 15 | 13 | 11 | 10 | 11 | 11 | 12 | 14 | 15 | 13 |
| Payable Days | 96 | 92 | 100 | 89 | 82 | 114 | 142 | 141 | 142 | 146 |
Metropolis Healthcare Limited is one of leading and renowned Indian diagnostics companies. The company owns a chain of diagnostic ce9ntres across India, South Asia, Africa and the Middle East. Over the years, Metropolis has carved a niche for itself. The company enjoys a loyal customer base, reflecting its strength as a brand offering superior diagnostic tests and services.
With its widespread operational network, Metropolis offers a comprehensive range of clinical laboratory tests and profiles. These tests and profiles are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease. Metropolis plays a pivotal role in raising the bar of diagnostic accuracy, technological equipment, customer experience and research-driven empathetic service in the industry.
Business area of the company
Metropolis Healthcare is engaged in the business of providing pathology and related healthcare services. The profile comprises of a variety of test combinations which are specific to a disease or disorder as well as wellness profiles that are used for health and fitness screening. It classifies its tests into ‘routine’ tests such as blood chemistry analyses, blood cell counts and urine examination; ‘semi-specialized’ tests such as thyroid function tests, viral and bacterial cultures, histology, cytology and infectious disease tests; and ‘specialized’ tests such as tests for coagulation studies, autoimmunity tests, cytogenetics and molecular diagnostics. It is focused on providing reliable test results as well as value-added services such as home collection of specimens and online access to test reports. It also offers customized wellness packages to its institutional customers as per their requirement.
Services
Awards
FY2018-19
FY2019-20
Major Events & Milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
